<bill session="117" type="s" number="4446" updated="2022-12-29T17:48:34Z">
  <state datetime="2022-06-22">REFERRED</state>
  <status>
    <introduced datetime="2022-06-22"/>
  </status>
  <introduced datetime="2022-06-22"/>
  <titles>
    <title type="display">Modernizing the Accelerated Approval Pathway Act of 2022</title>
    <title type="short" as="introduced">Modernizing the Accelerated Approval Pathway Act of 2022</title>
    <title type="official" as="introduced">A bill to modernize the process of accelerated approval of a drug for a serious or life-threatening disease or condition.</title>
  </titles>
  <sponsor bioguide_id="C001035"/>
  <cosponsors>
    <cosponsor bioguide_id="K000384" joined="2022-06-22"/>
  </cosponsors>
  <actions>
    <action datetime="2022-06-22">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2022-06-22" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
      <reference ref="CR S3077-3078" label="Sponsor introductory remarks on measure"/>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="s" number="4348" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2022-10-21T20:38:39Z" status="Introduced in Senate">Modernizing the Accelerated Approval Pathway Act of 2022

This bill modifies provisions relating to the accelerated approval of drugs for serious or life-threatening diseases or conditions, including by requiring the Food and Drug Administration (FDA) to publish its reasons when it determines a postapproval study to be unnecessary. The bill also establishes a pilot program and an FDA council to support the development of drugs for rare diseases and ensure the appropriate use of the accelerated approval pathway, respectively.</summary>
</bill>
